S-<(2RS)-2,3-dihydroxypropyl>-Cys-OH | 23255-32-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: S-<(2RS)-2,3-dihydroxypropyl>-Cys-OH
• 英文别名: S-2,3-dihydroxypropyl-L-cysteine；S-<(2RS)-2,3-Dihydroxypropyl>-L-Cys-OH；S-(2.3-dihydroxypropyl)cysteine；s-Glycerylcysteine；(2R)-2-amino-3-(2,3-dihydroxypropylsulfanyl)propanoic acid
• CAS: 23255-32-5
• 化学式: C₆H₁₃NO₄S
• 分子量: 195.24
• InChiKey: GPWYBXDQHZIBPR-AKGZTFGVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  129
• 氢给体数：
  4
• 氢受体数：
  6

安全信息

• 海关编码：
  2930909090

反应信息

• 作为反应物：
  描述：

  9-芴甲基-N-琥珀酰亚胺基碳酸酯 、 S-<(2RS)-2,3-dihydroxypropyl>-Cys-OH 在 sodium carbonate 作用下， 以 乙腈 为溶剂， 反应 2.0h， 以23%的产率得到N-fluorenylmethoxycarbonyl-S-(2.3-dihydroxypropyl)cysteine
  参考文献：
  名称：

  Double conjugation strategy to incorporate lipid adjuvants into multiantigenic vaccines

  摘要：

  通过它们的N-末端连接多肽的共轭是生产分枝多抗原疫苗的一种有前途的技术。

  DOI：

  10.1039/c5sc03859f
• 作为产物：
  描述：

  S-<(2RS)-2,3-Dihydroxypropyl>-N^α-Boc-Cys-OBu^t 在 茴香硫醚 、 三氟乙酸 作用下， 反应 1.0h， 以17%的产率得到S-<(2RS)-2,3-dihydroxypropyl>-Cys-OH
  参考文献：
  名称：

  具有微生物来源的免疫活性脂肽WS1279的结构和合成。

  摘要：

  WS1279的结构，分离自链霉菌。作为免疫活性脂肽，已经根据化学和物理证据推导为S- [2,3-双（棕榈酰氧基）丙基] -Nα-棕榈酰-Cys-Asn-Ser-Gly-Gly-Ser-OH。通过合成证实了这一点。

  DOI：

  10.1248/cpb.39.607

文献信息

• [EN] ADMINISTRATION OF A TLR2 AGONIST FOR THE TREATMENT OR PREVENTION OF A RESPIRATORY CONDITION ASSOCIATED WITH AN INFECTIOUS AGENT<br/>[FR] ADMINISTRATION D'UN AGONISTE DE TLR2 PERMETTANT LE TRAITEMENT OU LA PRÉVENTION D'AFFECTIONS RESPIRATOIRES ASSOCIÉES À UN AGENT INFECTIEUX
  申请人：ENA THERAPEUTICS PTY LTD

  公开号：WO2019119069A1

  公开（公告）日：2019-06-27

  The present invention relates to methods of treating or preventing respiratory conditions. In particular, the methods relate to treatment of respiratory conditions associated with a virus, such as influenza. In particular, the present invention provides a method of treating or preventing a respiratory condition associated with an infectious agent in an individual, the method comprising administering a compound comprising a TLR2 agonist to the upper respiratory tract of the individual, thereby treating or preventing a respiratory condition associated with an infectious agent in the individual. The compound is not administered to the lower respiratory tract or to both the upper and lower respiratory tract (i.e. administered to the total respiratory tract).

  本发明涉及治疗或预防呼吸道疾病的方法。具体而言，这些方法涉及治疗与病毒（如流感）相关的呼吸道疾病。具体而言，本发明提供了一种治疗或预防与感染性因子相关的个体呼吸道疾病的方法，该方法包括向个体的上呼吸道给予含有TLR2激动剂的化合物，从而治疗或预防个体中与感染性因子相关的呼吸道疾病。该化合物不会被给予下呼吸道，也不会同时给予上呼吸道和下呼吸道（即给予整个呼吸道）。
• <i>S</i>-Carboxymethylcysteine Synthase from<i>Escherichia coli</i>
  作者：Hidehiko Kumagai、Hideyuki Suzuki、Hiroki Shigematsu、Tatsurokuro Tochikura

  DOI：10.1080/00021369.1989.10869692

  日期：1989.9

  An enzyme that catalyzes the synthesis of S-carboxymethyl- l-cysteine from 3-chloro- l-alanine (3-Cl-Ala) and thioglycolic acid was found in Escherichia coli W3110 and was designated as S- carboxymethyl-l-cysteine synthase. It was purified from the cell-free extract to electrophoretic homogeneity and was crystallized. The enzyme has a molecular weight of 84,000 and gave one band corresponding to a molecular weight of 37,000 on SDS-polyacrylamide gel electrophoresis. The purified enzyme catalyzed the β-replacement reactions between 3-CI-AIa and various thiol compounds. The apparent Km values for 3-Cl-Ala and thioglycolic acid were 40 mM and 15.4 mM. The enzyme showed very low activity as to the α,β-elimination reaction with 3-Cl-Ala and l-serine. It was not inactivated on the incubation with 3-Cl-Ala. The absorption spectrum of the enzyme shows a maximum at 412 nm, indicating that it contains pyridoxal phosphate as a cofactor. The N-terminal amino acid sequence was determined and the corresponding sequence was detected in the protein sequence data bank, but no homogeneous sequence was found.

  在大肠杆菌 W3110 中发现了一种催化从 3-氯- l-丙氨酸（3-Cl-Ala）和巯基乙酸合成 S-羧甲基-l-半胱氨酸的酶，该酶被命名为 S-羧甲基-l-半胱氨酸合成酶。它从无细胞提取物中纯化到电泳纯度，并进行了结晶。该酶的分子量为 84,000，并在 SDS-聚丙烯酰胺凝胶电泳中显示出一个对应于 37,000 的带。纯化后的酶催化了 3-Cl-Ala 与多种硫醇化合物之间的β取代反应。3-Cl-Ala 和巯基乙酸的表观 Km 值分别为 40 mM 和 15.4 mM。该酶对 3-Cl-Ala 和 l-丝氨酸的 α,β 消除反应显示出非常低的活性。在与 3-Cl-Ala 孵育后并未失活。该酶的吸收光谱在 412 nm 处显示出最大值，表明它含有作为辅因子的磷酸吡哆醛。N 末端氨基酸序列已被确定，对应的序列在蛋白质序列数据库中被检出，但没有找到同源序列。
• CONJUGATED TLR7 AND/OR TLR8 AND TLR2 AGONISTS
  申请人：CAYLA

  公开号：US20140141033A1

  公开（公告）日：2014-05-22

  A conjugated compound of formula Q-Z—R 4 wherein Q is a TLR7 and/or TLR8 agonist and Z—R 4 is a TLR2 agonist, and the uses thereof in the treatment of infection, cancer or immune disorders or for use in vaccines.

  一种配方为Q-Z—R4的共轭化合物，其中Q是TLR7和/或TLR8激动剂，Z—R4是TLR2激动剂，以及它们在治疗感染、癌症或免疫紊乱或用于疫苗中的用途。
• SYNTHETIC IMMUNOGEN USEFUL FOR GENERATING LONG LASTING IMMUNITY AND PROTECTION AGAINST PATHOGENS
  申请人：Agrewala Javed Naim

  公开号：US20130183377A1

  公开（公告）日：2013-07-18

  The present invention relates to a synthetic immunogen represented by the general formula 1, useful for generating long lasting protective immunity against various intracellular pathogens which are the causative agents of tuberculosis, leishmaniasis, AIDS, trypanosomiasis, malaria and also allergy, cancer and a process for the preparation thereof. The developed immunogen is able to circumvent HLA restriction in humans and livestock. The invention further relates to a vaccine comprising the said immunogen for generating enduring protective immunity against various diseases. The said vaccine is targeted against intracellular pathogens, more particularly the pathogen M. tuberculosis in this case. In the present invention, promiscuous peptides of M. tuberculosis are conjugated to TLR ligands especially; Pam2Cys to target them mainly to dendritic cells and therefore elicit long-lasting protective immunity. (The formula (I) should be inserted here) General formula (I) wherein, X 1 =a promiscuous CD4 T helper epitope selected from SEQ ID No. 1 to 98 OR nil; X 2 =a promiscuous CD8 T cytotoxic epitope selected from SEQ ID No. 99 to 103 OR nil; when X1=nil; X2=SEQ ID No. 99 to 103 and when X2=nil; X1=SEQ ID No. 1 to 98; Y=Lysine; and S=Serine.

  本发明涉及一种由通式1表示的合成免疫原，可用于产生长期的保护性免疫力，以对抗导致结核病、利什曼病、艾滋病、锥虫病、疟疾、过敏和癌症等各种细胞内病原体。所开发的免疫原能够规避人类和家畜的HLA限制。本发明还涉及一种包括所述免疫原的疫苗，用于产生长期的保护性免疫力以对抗各种疾病。该疫苗针对细胞内病原体，特别是在本例中的M. tuberculosis病原体。在本发明中，M. tuberculosis的杂交肽与TLR配体（尤其是Pam2Cys）结合，主要靶向树突状细胞，从而引发长期的保护性免疫力。（公式（I）应在此处插入）通式（I）其中，X1 = SEQ ID No. 1至98或nil中选择的杂交CD4 T辅助表位；X2 = SEQ ID No. 99至103或nil中选择的杂交CD8 T细胞毒性表位；当X1 = nil时，X2 = SEQ ID No. 99至103，当X2 = nil时，X1 = SEQ ID No. 1至98；Y = 赖氨酸；S = 丝氨酸。
• Adjuvanting Material
  申请人：Jackson David C.

  公开号：US20080233143A1

  公开（公告）日：2008-09-25

  The present invention provides an adjuvanting material, the adjuvanting material comprising a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group. Further, the present invention provides an immunogenic composition comprising (a) a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group; (b) an antigen comprising a metal affinity tag; and optionally (c) metal ions, whereby the antigen is linked to the lipid dendritic cell targeting moiety via the interaction between the metal affinity tag and the metal chelating group.

  本发明提供了一种辅助材料，该辅助材料包括一个脂质树突状细胞靶向基团，其中与之共价结合的是一个金属螯合基团。此外，本发明还提供了一种免疫原组合物，包括（a）一个脂质树突状细胞靶向基团，其中与之共价结合的是一个金属螯合基团；（b）一个包含金属亲和标签的抗原；以及可选的（c）金属离子，因此抗原通过金属亲和标签和金属螯合基团之间的相互作用与脂质树突状细胞靶向基团连接。